BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 35876221)

  • 1. Multivalent, Bispecific αB7-H3-αCD3 Chemically Self-Assembled Nanorings Direct Potent T Cell Responses against Medulloblastoma.
    Mews EA; Beckmann P; Patchava M; Wang Y; Largaespada DA; Wagner CR
    ACS Nano; 2022 Aug; 16(8):12185-12201. PubMed ID: 35876221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eradication of Established Tumors by Chemically Self-Assembled Nanoring Labeled T Cells.
    Petersburg JR; Shen J; Csizmar CM; Murphy KA; Spanier J; Gabrielse K; Griffith TS; Fife B; Wagner CR
    ACS Nano; 2018 Jul; 12(7):6563-6576. PubMed ID: 29792808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eradication of Heterogeneous Tumors by T Cells Targeted with Combination Bispecific Chemically Self-assembled Nanorings.
    Petersburg J; Vallera DA; Wagner CR
    Mol Cancer Ther; 2023 Mar; 22(3):371-380. PubMed ID: 36548194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-EGFR Fibronectin Bispecific Chemically Self-Assembling Nanorings (CSANs) Induce Potent T Cell-Mediated Antitumor Responses and Downregulation of EGFR Signaling and PD-1/PD-L1 Expression.
    Kilic O; Matos de Souza MR; Almotlak AA; Wang Y; Siegfried JM; Distefano MD; Wagner CR
    J Med Chem; 2020 Sep; 63(18):10235-10245. PubMed ID: 32852209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.
    Majzner RG; Theruvath JL; Nellan A; Heitzeneder S; Cui Y; Mount CW; Rietberg SP; Linde MH; Xu P; Rota C; Sotillo E; Labanieh L; Lee DW; Orentas RJ; Dimitrov DS; Zhu Z; Croix BS; Delaidelli A; Sekunova A; Bonvini E; Mitra SS; Quezado MM; Majeti R; Monje M; Sorensen PHB; Maris JM; Mackall CL
    Clin Cancer Res; 2019 Apr; 25(8):2560-2574. PubMed ID: 30655315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-Stimulatory Bispecific Antibodies Induce Enhanced T Cell Activation and Tumor Cell Killing in Breast Cancer Models.
    Warwas KM; Meyer M; Gonçalves M; Moldenhauer G; Bulbuc N; Knabe S; Luckner-Minden C; Ziegelmeier C; Heussel CP; Zörnig I; Jäger D; Momburg F
    Front Immunol; 2021; 12():719116. PubMed ID: 34484225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The making of multivalent gamma delta TCR anti-CD3 bispecific T cell engagers.
    van Diest E; Nicolasen MJT; Kramer L; Zheng J; Hernández-López P; Beringer DX; Kuball J
    Front Immunol; 2022; 13():1052090. PubMed ID: 36685546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemically self-assembled antibody nanorings (CSANs): design and characterization of an anti-CD3 IgM biomimetic.
    Li Q; So CR; Fegan A; Cody V; Sarikaya M; Vallera DA; Wagner CR
    J Am Chem Soc; 2010 Dec; 132(48):17247-57. PubMed ID: 21077608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pediatric medulloblastoma express immune checkpoint B7-H3.
    Li S; Poolen GC; van Vliet LC; Schipper JG; Broekhuizen R; Monnikhof M; Van Hecke W; Vermeulen JF; Bovenschen N
    Clin Transl Oncol; 2022 Jun; 24(6):1204-1208. PubMed ID: 34988920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Anti-B7-H3 × Anti-CD3 Bispecific Antibody with Potent Antitumor Activity.
    Feng Y; Xie K; Yin Y; Li B; Pi C; Xu X; Huang T; Zhang J; Wang B; Gu H; Fang J
    Life (Basel); 2022 Jan; 12(2):. PubMed ID: 35207448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bispecific T cell engager-armed T cells targeting integrin ανβ6 exhibit enhanced T cell redirection and antitumor activity in cholangiocarcinoma.
    Suwanchiwasiri K; Phanthaphol N; Somboonpatarakun C; Yuti P; Sujjitjoon J; Luangwattananun P; Maher J; Yenchitsomanus PT; Junking M
    Biomed Pharmacother; 2024 May; 175():116718. PubMed ID: 38744221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors.
    Yang M; Tang X; Zhang Z; Gu L; Wei H; Zhao S; Zhong K; Mu M; Huang C; Jiang C; Xu J; Guo G; Zhou L; Tong A
    Theranostics; 2020; 10(17):7622-7634. PubMed ID: 32685008
    [No Abstract]   [Full Text] [Related]  

  • 13. Engineering reversible cell-cell interactions using enzymatically lipidated chemically self-assembled nanorings.
    Wang Y; Kilic O; Csizmar CM; Ashok S; Hougland JL; Distefano MD; Wagner CR
    Chem Sci; 2020 Oct; 12(1):331-340. PubMed ID: 34168743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bispecific anti-CD3 x anti-B7-H3 antibody mediates T cell cytotoxic ability to human melanoma in vitro and in vivo.
    Ma J; Shang T; Ma P; Sun X; Zhao J; Sun X; Zhang M
    Invest New Drugs; 2019 Oct; 37(5):1036-1043. PubMed ID: 30706335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.
    Iizuka A; Nonomura C; Ashizawa T; Kondou R; Ohshima K; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Akiyama Y
    Clin Cancer Res; 2019 May; 25(9):2925-2934. PubMed ID: 30737243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MEK Inhibitor Augments Antitumor Activity of B7-H3-Redirected Bispecific Antibody.
    Li H; Huang C; Zhang Z; Feng Y; Wang Z; Tang X; Zhong K; Hu Y; Guo G; Zhou L; Guo W; Xu J; Yang H; Tong A
    Front Oncol; 2020; 10():1527. PubMed ID: 32984002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting immunotherapy for bladder cancer using anti-CD3× B7-H3 bispecific antibody.
    Ma W; Ma J; Ma P; Lei T; Zhao M; Zhang M
    Cancer Med; 2018 Oct; 7(10):5167-5177. PubMed ID: 30253078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mRNA-based precision targeting of neoantigens and tumor-associated antigens in malignant brain tumors.
    Trivedi V; Yang C; Klippel K; Yegorov O; von Roemeling C; Hoang-Minh L; Fenton G; Ogando-Rivas E; Castillo P; Moore G; Long-James K; Dyson K; Doonan B; Flores C; Mitchell DA
    Genome Med; 2024 Jan; 16(1):17. PubMed ID: 38268001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B7-H3 in Brain Malignancies: Immunology and Immunotherapy.
    Guo X; Chang M; Wang Y; Xing B; Ma W
    Int J Biol Sci; 2023; 19(12):3762-3780. PubMed ID: 37564196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of T cells secreting αCD133-αCD3 bispecific T-cell engager against cholangiocarcinoma.
    Sangsuwannukul T; Supimon K; Chieochansin T; Choomee K; Sujjitjoon J; Junking M; Yenchitsomanus PT
    PLoS One; 2022; 17(3):e0265773. PubMed ID: 35312724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.